MARKET

HRTX

HRTX

Heron Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.14
-0.10
-0.66%
After Hours: 15.66 +0.52 +3.43% 18:46 10/19 EDT
OPEN
15.38
PREV CLOSE
15.24
HIGH
15.45
LOW
14.93
VOLUME
512.49K
TURNOVER
--
52 WEEK HIGH
26.81
52 WEEK LOW
9.60
MARKET CAP
1.38B
P/E (TTM)
-6.7340
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shift From Loss To Profit
We feel now is a pretty good time to analyse Heron Therapeutics, Inc.'s (NASDAQ:HRTX) business as it appears the...
Simply Wall St. · 5d ago
Heron Therapeutics Inc (HRTX): Hedge Funds Are Nibbling
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress
Insider Monkey · 10/06 22:05
Heron's (HRTX) Pain Drug Zynrelef Gets EU Approval, Shares Up
Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.
Zacks · 09/29 16:42
Heron's Zynrelef OK'd in Europe for post-op pain
As expected, the European Commission approves Heron Therapeutics' ([[HRTX]] +0.9%) Zynrelef (formerly HTX-011), a fixed-dose combination of local anesthetic bupivacaine and nonsteroidal anti-inflammatory med meloxicam, for the treatment of postoperative
Seekingalpha · 09/28 13:39
Heron Therapeutics Receives European Commission Authorization for ZYNRELEF (HTX-011) for the Treatment of Postoperative Pain
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the European Commission has granted a marketing authorization
PR Newswire · 09/28 13:30
Heron Therapeutics Receives European Commission Authorization For ZYNRELEF For The Treatment Of Postoperative Pain
SAN DIEGO, Sept. 28, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to
Benzinga · 09/28 12:35
Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the results from EPOCH 2 follow-on study (NCT03695367) of
PR Newswire · 09/16 13:30
Heron Therapeutics Highlights Publication Of Results From EPOCH 2 Follow-On Study, A Phase 2b Study Of HTX-011 In Patients Undergoing Hernia Repair Surgery
SAN DIEGO, Sept. 16, 2020 /PRNewswire/ --Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to
Benzinga · 09/16 12:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HRTX. Analyze the recent business situations of Heron Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HRTX stock price target is 31.20 with a high estimate of 70.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 287
Institutional Holdings: 106.31M
% Owned: 117.01%
Shares Outstanding: 90.86M
TypeInstitutionsShares
Increased
69
6.66M
New
71
-1.21M
Decreased
54
9.48M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
Chairman/Chief Executive Officer/Director
Barry Quart
President
John Poyhonen
Chief Financial Officer/Senior Vice President - Finance
Robert Hoffman
Chief Operating Officer/Executive Vice President
David Szekeres
Executive Vice President/Director
Kimberly Manhard
Senior Vice President/Chief Scientific Officer
Thomas Ottoboni
Senior Vice President
Anita Gupta
Senior Vice President
Michael Mathews
Chief Accounting Officer/Vice President
Lisa Peraza
Vice President/Director of Human Resources
Sean Ristine
Vice President
John Arthur
Other
Christopher Storgard
Lead Director/Independent Director
Craig Johnson
Director
Steve Davis
Independent Director
Stephen Davis
Independent Director
Christian Waage
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HRTX
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Heron Therapeutics Inc stock information, including NASDAQ:HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.